Your Yearly Kidney MRI: Why Screening Matters So Much in HLRCC

If you or someone you love carries a change in the FH gene, you’ve probably heard the words “annual MRI” more than once. It can feel like one more appointment, one more hour in a noisy tube, one more wait for results. But that yearly scan is one of the most powerful things our community has. Here’s why the experts recommend it, and what the guidelines say.
Why HLRCC kidney cancer needs early detection
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is caused by an inherited change in the FH (fumarate hydratase) gene. People with HLRCC can develop benign skin and uterine leiomyomas (fibroids), and they have a higher risk of a particular kind of kidney cancer.
An international expert group led by Dr. F.H. Menko of the Netherlands Cancer Institute and colleagues, including Dr. W.M. Linehan of the National Cancer Institute, estimated the lifetime kidney cancer risk for FH variant carriers at about 15%. A more recent review in Clinical Cancer Research (2025) put the age-related risk at about 1% by age 15, 2% by age 20 and 21% by age 70.
That means most people with HLRCC do not get kidney cancer. But when it does happen, it’s serious. The 2025 review describes HLRCC kidney tumors as typically aggressive, with poor outcomes that often reflect cancers found late, after symptoms appear. The same review notes that in studies where people had regular kidney imaging, cancers were found and the patients were alive when the studies were reported.
The goal of screening is simple: find a tumor while it’s small and treatable, before it causes symptoms.
What the guidelines recommend
The 2014 consensus and the 2025 review both recommend a dedicated kidney MRI once a year. NCI PDQ also supports regular renal imaging and notes that MRI may be preferred over CT to limit radiation over a lifetime of screening.
- Why MRI, not ultrasound? The 2025 review says MRI is preferred because ultrasound is less sensitive at picking up HLRCC kidney tumors. The 2014 consensus also recommended annual abdominal MRI.
- Contrast or no contrast? The 2025 pediatric consensus recommends routine screening scans without contrast, using a technique called diffusion-weighted imaging to help spot small lesions. If something is found, a follow-up MRI with contrast is done to take a closer look. Your own care team may use a different protocol, so ask them what’s right for you.
- What has screening shown? According to the 2025 review, an evaluation of HLRCC kidney screening found it to be both sensitive and specific, with no cancers reported between scans and no extra findings that needed invasive testing.
When should children start?
This is one of the questions families ask most. The 2014 consensus recommended kidney imaging, and predictive genetic testing when available, starting at age 8 to 10. It also said the small risk in the 10 to 20 age range and the possible downsides of screening should be talked through with each family.
The 2025 review, from the 2023 American Association for Cancer Research Childhood Cancer Predisposition Workshop, agreed that annual kidney MRI should begin at around age 10. It notes that 15 children under 18 had been reported in the medical literature with HLRCC kidney cancer, all in their teens except one child who was 7. It also cites research finding that annual MRI starting at age 8 was cost-effective.
NCI PDQ says the age to start renal screening is uncertain and records the HLRCC Family Alliance recommendation of annual imaging beginning at age 8. GeneReviews (FH Tumor Predisposition Syndrome, updated 2025) also discusses annual renal MRI and should be read with your care team, who decide timing.
If you have children, a genetic counselor can help you decide when testing and screening make sense for your family.
If something is found
Finding a spot on an MRI can be frightening. In HLRCC, the guidelines are clear that a suspicious kidney tumor calls for prompt action. Unlike some other hereditary kidney cancer syndromes, where small tumors may simply be watched, the 2025 review recommends prompt surgery with wide margins, whatever the size of the tumor. The 2014 consensus said the same and added that surgeons should consider removing nearby lymph nodes.
That’s why it matters to have your scans read, and any surgery planned, by a team that knows HLRCC.
Making your yearly scan easier
A few practical tips:
- Put it on the calendar. Many families tie their scan to a birthday or the same month every year so it doesn’t slip.
- Ask for a dedicated kidney MRI, not a general scan, and tell the imaging center you have HLRCC.
- Keep your reports. Copies of past scans help radiologists compare from year to year, especially if you change hospitals.
- Don’t wait for the next scan if something changes. The 2025 review advises families to seek care for symptoms like persistent pain or a growing mass.
The bottom line
The annual MRI isn’t anyone’s favorite appointment. But for people with HLRCC, expert groups recommend a yearly kidney MRI to look for tumors early, when they may still be small and treatable. Every scan on the calendar is a step toward protecting yourself and your family.
For a wider, head-to-toe look at screening and follow-up in HLRCC, see Staying Ahead of HLRCC.
Join us
You don’t have to manage HLRCC alone. Join our community in the HLRCC Foundation: Knowledge Saves Facebook group, learn more on our genetic testing page, and if you’d like to support awareness and research, please consider donating.
This article is for general education and is not medical advice. Please talk with your own doctors and genetic counselor about the screening plan that’s right for you.
Sources
- Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomäki K, Tomlinson I, Richard S, Linehan WM. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637–644. doi:10.1007/s10689-014-9735-2. Free full text
- Michaeli O, Kim SY, Mitchell SG, et al.; Woodward ER, Stewart DR. Update on cancer screening in children with syndromes of bone lesions, hereditary leiomyomatosis and renal cell carcinoma syndrome, and other rare syndromes. Clin Cancer Res. 2025;31(3):457–465. doi:10.1158/1078-0432.CCR-24-2171. PubMed: 39601780. Free full text
- Kamihara J, Schultz KA, Rana HQ. FH Tumor Predisposition Syndrome. GeneReviews®. University of Washington, Seattle; updated 2025. NBK1252
- National Cancer Institute. Hereditary Leiomyomatosis and Renal Cell Cancer (PDQ®)–Health Professional Version. PDQ Cancer Genetics Editorial Board; updated November 6, 2024.